Patent•
Applications of stimulator of interferon genes (STING) agonists in preventing diseases such as rheumatoid arthritis
29 Mar 2017-
TL;DR: In this article, a stimulator of interferon genes (STING) agonists, including cyclic dinucleotides cGAMP, c-di-AMP, and sulfur-substituted derivatives thereof, was used for treating rheumatoid arthritis.
Abstract: The invention belongs to the field of medical technology, and more specifically relates to applications of stimulator of interferon genes (STING) agonists, including cyclic dinucleotides cGAMP, c-di-AMP, c-di-GMP, and sulfur-substituted derivatives thereof in treating autoimmune diseases such as rheumatoid arthritis. It is shown in the invention that the STING agonists are capable of inhibiting arthrocele, reducing arthritis index, and realizing down-regulated expression of IL-17, TNF-alpha, IL-1beta, and IL-6, so that the STING agonists can be used for preparing drugs used for treating autoimmune diseases such as rheumatoid arthritis.
Citations
More filters
Patent•
10 Feb 2016TL;DR: In this paper, the authors proposed a new strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme and the preferred expression vector is a mycobacterial expression vector including an hsp60 promoter and a DNA sequence of disA.
Abstract: The present invention includes the discovery of a strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme. The Mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium bovis , or a combination thereof and the preferred strain of Mycobacterium is BCG. The preferred expression vector is a mycobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains of Mycobacterium are used in therapeutic applications including tuberculosis and cancer.
3 citations
Patent•
01 Oct 2018TL;DR: Methods of treating or preventing cancer in a subject comprising administering to the subject an effective amount of a bacteria comprising and expression vector encoding a di-adenylate cyclase enzyme are described.
Abstract: Described herein are methods of treating or preventing cancer in a subject comprising administering to the subject an effective amount of a bacteria comprising and expression vector encoding a di-adenylate cyclase enzyme.
References
More filters
Patent•
13 Dec 2013
TL;DR: In this paper, a cyclic-di-nucleotide (CDN) immune stimulator that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes).
Abstract: It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.
106 citations
Patent•
02 May 2014TL;DR: In this paper, methods and compositions for increasing the production of a type I interferon (IFN) in a cell were provided. And compositions and kits for practicing the embodiments of the methods are provided.
Abstract: Methods and compositions are provided for increasing the production of a type I interferon (IFN) in a cell Aspects of the methods include increasing the level of a 2'-5' phosphodiester linkage comprising cyclic-di-nucleotide in a cell in a manner sufficient to increase production of the type I interferon (IFN) by the cell Also provided are compositions and kits for practicing the embodiments of the methods
92 citations
TL;DR: Evidence is provided that IFN-β has some beneficial therapeutic effect in patients with relapsing-remitting multiple sclerosis and might also have antirheumatic potential, supported by recent studies showing a critical role for IFn-β in bone homeostasis.
Abstract: IFN-β treatment is emerging as a potentially effective form of therapy in various immune-mediated conditions. The present review addresses the possible role of IFN-β in immune-mediated diseases such as multiple sclerosis and rheumatoid arthritis. Several placebo-controlled trials are discussed, as are the available immunological data that are relevant to this field. Review of these data provides evidence that IFN-β has some beneficial therapeutic effect in patients with relapsing-remitting multiple sclerosis and might also have antirheumatic potential. This notion is supported by recent studies showing a critical role for IFN-β in bone homeostasis.
66 citations
Patent•
09 Jul 2014TL;DR: In this paper, the cyclic dinucleotide cGAMP has been used for the preparation of anti-tumor medicaments, which have the advantages of low toxicity and good effect.
Abstract: The invention belongs to the technical field of medicines, and in particular relates to an application of cyclic dinucleotide cGAMP in preparing anti-tumor medicaments. Researches indicate that cGAMP can be used for inhibiting growth of multiple tumor cells, has a remarkable anti-tumor effect, and can be used for preparing anti-tumor medicaments; the prepared anti-tumor medicaments have the advantages of low toxicity and good effect. Studies on a subcutaneous tumor model in nude mice indicate that the cGAMP has remarkable inhibiting effects on the human stomach cancer cell line MNK-45, the human lung adenocarcinoma cell line A549, the human colonic carcinoma cell line Lovo, the human hepatocellular carcinoma cell SMMC-7721, the human prostatic carcinoma cell line PC-3 and the human pancreatic cancer cells SW1990 of subcutaneous transplanted tumors in the nude mice; animal acute toxin experiments indicate that the acute toxicity of the cGAMP is relatively low, so that the cGAMP can be used for preparing anti-tumor medicaments.
20 citations